Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diversity of Antigen Receptors

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.

Nature communications·2026

Same author

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Nature communications·2026

Same author

Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.

Journal of personalized medicine·2025

Same author

Bispecific antibody combination therapies in diffuse large B-cell lymphoma.

British journal of haematology·2025

Same author

Targeting PTPN2 enhances human CAR T cell efficacy and the development of long-term memory in mouse xenograft models.

Science translational medicine·2025

Same author

Parity and lactation induce T-cell-mediated breast cancer protection.

Nature·2025

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Chimeric Antigen Receptor beyond CAR-T Cells.

Vicky Mengfei Qin^1,2, Criselle D'Souza^1,3, Paul J Neeson^1,3

¹Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

|January 27, 2021

Summary

This summary is machine-generated.

Chimeric antigen receptor (CAR) technology is expanding beyond T cells. Engineering other immune cells like NK and B cells with CARs shows promise for treating cancers and autoimmune diseases.

Keywords:

chimeric antigen receptor combination therapy endodomain immune cell

More Related Videos

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Jun 22, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Immunotherapy
Cellular Engineering
Oncology

Background:

Chimeric antigen receptors (CARs) enable immune cells to target specific antigens.
CAR-T cell therapy is effective for hematologic cancers but limited for solid tumors.
Research is exploring CAR applications beyond T cells.

Purpose of the Study:

To review the recent applications of CAR design in non-T immune cells.
To discuss future opportunities for CAR technology in immunotherapy.

Main Methods:

Review of preclinical and clinical studies on CAR-engineered non-T cells.
Analysis of CAR technology's potential in various immune cell types.

Main Results:

CAR-engineered NK/NKT and γδ T cells show direct anti-tumor responses.
CAR-Tregs demonstrate therapeutic potential for autoimmune diseases.
CAR-engineered B cells offer a platform for sustained therapeutic protein delivery.

Conclusions:

CAR technology is a powerful immunotherapy platform with broad applications.
Expanding CAR design to non-T cells opens new avenues for cancer and autoimmune disease treatment.